Acadia Pharmaceuticals
ACAD
267 hedge funds and large institutions have $6.19B invested in Acadia Pharmaceuticals in 2020 Q3 according to their latest regulatory filings, with 53 funds opening new positions, 103 increasing their positions, 85 reducing their positions, and 81 closing their positions.
21% more repeat investments, than reductions
Existing positions increased: 103 | Existing positions reduced: 85
17% more funds holding in top 10
Funds holding in top 10: 6 → 7 (+1)
3.55% less ownership
Funds ownership: 98.03% → 94.48% (-3.5%)
10% less funds holding
Funds holding: 298 → 267 (-31)
16% less capital invested
Capital invested by funds: $7.4B → $6.19B (-$1.21B)
27% less call options, than puts
Call options by funds: $33M | Put options by funds: $45.2M
35% less first-time investments, than exits
New positions opened: 53 | Existing positions closed: 81
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Janus Henderson Group
London,
|
+$77.6M |
| 2 |
MWNA
Marshall Wace North America
New York
|
+$51.6M |
| 3 |
Marshall Wace
London,
United Kingdom
|
+$40.3M |
| 4 |
FAM
Fred Alger Management
New York
|
+$37.3M |
| 5 |
Thrivent Financial for Lutherans
Minneapolis,
Minnesota
|
+$33.5M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Citadel Advisors
Miami,
Florida
|
-$56M |
| 2 |
HM
HealthCor Management
New York
|
-$49.7M |
| 3 |
Fidelity Investments
Boston,
Massachusetts
|
-$45M |
| 4 |
Ameriprise
Minneapolis,
Minnesota
|
-$41.1M |
| 5 |
T. Rowe Price Associates
Baltimore,
Maryland
|
-$34.7M |
ACAD Hedge Fund Activity: Q3 2020 in Review
267 of the 4,970 institutional investors tracked by Wall St. Rank reported a position in Acadia Pharmaceuticals (ACAD) for Q3 2020, worth a combined $6.19B — down 16% from $7.4B a quarter earlier.
Sellers outnumbered buyers: 81 funds closed out of ACAD and 53 opened new positions — a net loss of 28 holders — while 85 trimmed existing stakes and 103 added.
The largest buyer was Janus Henderson Group, adding an estimated $77.6M. The largest seller was Citadel Advisors, cutting an estimated $56M.
- 267 institutional investors held Acadia Pharmaceuticals (ACAD) as of Q3 2020, down from 298 in Q2 2020.
- Funds reported $6.19B of Acadia Pharmaceuticals stock for Q3 2020, down 16% quarter-over-quarter.
- 53 funds opened new Acadia Pharmaceuticals positions in Q3 2020 and 81 closed out, a net change of -28 holders.
- The largest Acadia Pharmaceuticals buyer in Q3 2020 was Janus Henderson Group, an estimated $77.6M added.
- The largest Acadia Pharmaceuticals seller in Q3 2020 was Citadel Advisors, an estimated $56M sold.
Based on aggregated 13F filings for Q3 2020.